Zealand Pharma’s shares plummeted by a record 32% following disappointing data from a Phase 2 trial of its obesity drug, petrelintide, which was tested on overweight and obesity patients without type 2 diabetes. The company is co-developing petrelintide in partnership with Roche, and despite this setback, Zealand Pharma continues to advance its obesity portfolio, including trials for another drug, survodutide, anticipated throughout the year.
Securitize’s Head of Ecosystem, Graham Ferguson, announced that the company is collaborating with some of the largest asset managers to facilitate the tokenization of financial products. This effort is part of a broader trend where […]
Soccer icon Cristiano Ronaldo has made headlines by acquiring a 10% equity stake in Pro2col through a $7.5 million investment, underscoring a growing trend of personalized digital wellness solutions. This move aligns with insights from […]
In a move to address a legislative stalemate, the Digital Chamber, a crypto industry group, has drafted a set of stablecoin principles to counter Wall Street bankers’ stance against stablecoin rewards in the U.S. Senate’s […]